Logo

Theravance Reports First Patient Dosing in a P-II Study of TD-0903 for Hospitalized Patients with Acute Lung Injury Associated with COVID-19

Share this

Theravance Reports First Patient Dosing in a P-II Study of TD-0903 for Hospitalized Patients with Acute Lung Injury Associated with COVID-19

Shots:

  • The first patient has been dosed in a P-II study of TD-0903. The P-II study consists of two parts: the first part will assess the safety- tolerability- and clinical response to treatment in sequential ascending dose cohorts of hospitalized COVID-19 patients- with each patient demonstrating hypoxia being dosed for 7 days
  • The second part will be conducted at hospital-based clinical sites in the UK- EU & the US- pending appropriate Ethics Committee- and regulatory approvals in territories. The P-II study in the UK follows the completion of dosing in the P-I study in healthy volunteers
  • TD-0903 is a lung-selective- nebulized pan-JAK inhibitor- being developed to treat hospitalized patients with ALI caused by COVID-19

Click here to read full press release/ article | Ref: Theravance | Image: Theravance


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions